Daniel J. George, MD, discusses the potential use of lutetium-177 earlier in the treatment paradigm for metastatic castration-resistant prostate cancer.
Daniel George, MD
Advertisement
Articles by Daniel George, MD
Daniel J. George, MD, discusses the phase 3b CheckMate 8Y8 study of nivolumab plus ipilimumab vs nivolumab alone in previously untreated advanced RCC
Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.
Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. George on the Specificity of Cabozantinib in RCCPublished: November 13th 2020 | Updated:
Dr George on Other Potential Roles for Radioligand Therapy in Prostate CancerPublished: September 30th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
4
Dr Neff on the Accuracy and Feasibility of Self-Collected HPV Testing in Cervical Cancer
5